RBC Capital Defending Sarepta Therapeutics (SRPT), 'we see value in SRPT's gene therapy programs that is not captured at current levels and remain buyers', PT $150
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $150.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
